About Us
Fresenius Kabi Global at a glance
Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. in the field of biosimilars, we develop product with a focus of autoimmune diseases and oncology.
Fresenius Kabi employs more than 37,000 people worldwide.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2018, the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
Key Figures
| € in millions | 2018 | 2017 |
| Sales | 6,544 | 6,358 |
| EBITDA1 | 1,434 | 1,483 |
| EBIT1 | 1,139 | 1,177 |
| Net Income 1,2 | 742 | 702 |
| Employees (Dec 31) | 37,843 | 36,380 |
1 Before special terms
2 Net income attributes to shareholders of Fresenius SE & Co. KGaA
